Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

-0.89 (-1.20%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
736,511 shs
Average Volume
946,703 shs
Market Capitalization
$7.08 billion
P/E Ratio
Dividend Yield
Price Target

Intra-Cellular Therapies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
23.3% Upside
$90.17 Price Target
Short Interest
3.58% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.73mentions of Intra-Cellular Therapies in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$11.36 M Sold Last Quarter
Proj. Earnings Growth
From ($0.62) to $0.90 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.30 out of 5 stars

Medical Sector

138th out of 909 stocks

Pharmaceutical Preparations Industry

49th out of 423 stocks

ITCI stock logo

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Stock Price History

ITCI Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Intra-Cellular Therapies Inc
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$462.18 million
Book Value
$6.15 per share


Free Float
Market Cap
$7.11 billion
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Sharon Mates Ph.D. (Age 71)
    Co-Founder, Chairman & CEO
    Comp: $2.23M
  • Mr. Michael I. Halstead J.D. (Age 51)
    Comp: $983.65k
  • Dr. Suresh K. Durgam M.D. (Age 55)
    Executive VP & Chief Medical Officer
    Comp: $961.84k
  • Mr. Mark NeumannMr. Mark Neumann (Age 61)
    EVP & Chief Commercial Officer
    Comp: $998.36k
  • Dr. Robert E. Davis Ph.D. (Age 73)
    Senior VP & Chief Scientific Officer
    Comp: $646.12k
  • Mr. Juan Fernando Sanchez (Age 53)
    Vice President of Corporate Communications & Investor Relations
    Comp: $296.75k
  • Ms. Karen Patruno Sheehy Esq. (Age 62)
    Senior VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Senior VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Senior VP of Market Access, Policy & Government Affairs
  • Dr. Willie R. Earley M.D.
    Senior VP & Head of Clinical Development

ITCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price target for 2024?

10 brokerages have issued twelve-month price targets for Intra-Cellular Therapies' shares. Their ITCI share price targets range from $62.00 to $120.00. On average, they predict the company's share price to reach $90.17 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2024?

Intra-Cellular Therapies' stock was trading at $71.62 at the beginning of 2024. Since then, ITCI stock has increased by 2.1% and is now trading at $73.12.
View the best growth stocks for 2024 here

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ITCI earnings forecast

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.14. The biopharmaceutical company earned $132.10 million during the quarter, compared to the consensus estimate of $135.97 million. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative trailing twelve-month return on equity of 23.02%. The firm's revenue was up 50.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.45) EPS.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different institutional and retail investors. Top institutional investors include Wasatch Advisors LP (3.98%), Assenagon Asset Management S.A. (0.67%), Raymond James & Associates (0.16%), Hennion & Walsh Asset Management Inc. (0.02%), Allspring Global Investments Holdings LLC (0.02%) and Los Angeles Capital Management LLC (0.02%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam.
View institutional ownership trends

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITCI) was last updated on 4/24/2024 by Staff

From Our Partners